Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
New Therapies and Current Patient Management of Lymphomas
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
ASH Updates on R/R cHL: How to Consider Pembro-GVH? What Is the Role of Radiation-Based Approaches? What Is the Feasibility of Targeting Multiple Pathways for Patients With Relapses?
FEATURING
Jakub Svoboda
- 86 views
- March 5, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
UPenn Expert Discussion on Lymphoma: Efficacy of Acalabrutinib for Severe COVID-19, Time-Limited Venetoclax / Obinutuzumab, Brentuximab Mono in HL
FEATURING
Stephen Schuster,
James Gerson,
Jakub Svoboda,
Elise Chong,
Sunita D. Nasta,
Douglas Beach,
Gamil Hanna
- 94 views
- March 3, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
ASH Updates on Large Cell & Aggressive Lymphomas: Antibody Loncastuximab Tesirine in R/R DLBCL, Glofitamab Step-Up Dosing in Hard-to-Treat R/R NHL, Subcutaneous Epcoritamab in R/R NHL, M-CHOP for DLBCL
FEATURING
Sunita D. Nasta
- 159 views
- March 2, 2021
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
ASH Updates on Lymphomas: 1L (Axi-Cel) in High-Risk DLBCL, Safety, Dosing and Feasibility of MB-CART2019 in R/R B-NHL, BTKi/mTOR/IMID Combo for R/R Richter's Transformation and De-Novo DLBCL, CNS Lymphoma Prevention, Primary CNS Lymphoma
FEATURING
Sunita D. Nasta
- 55 views
- March 2, 2021
